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UlmReduced-intensity conditioning allogeneic stem cell transplant (RIC-alloSCT) is being increasingly used for
patients with acute myelogenous leukemia (AML) with comorbidities. Few published data are currently
available regarding for the use of peripheral blood stem cells (PBSCs) compared to bone marrow (BM)
in the RIC-alloSCT using unrelated donors (URDs). This retrospective report compared the outcomes
of PBSC versus BM RIC-alloSCT. Between 2000 and 2007, 602 patients with AML in complete remission
(CR) underwent RIC-alloSCT from URDs with PBSC (508) or BM (94) grafts. Recipient’s age was higher in
the PBSC versus BM groups 57 (range, 17-77 years) and 51 (range, 17-76 years), respectively (P\.0001).
Leukemia features and disease status at RIC-alloSCTwere also comparable between the PBSC versus BM
groups. Engraftment was achieved in 97% and 96% with BM versus peripheral blood (PB), respectively.
Acute graft-versus-host disease (aGVHD) grade .II was significantly higher in the PBSC group: 27% versus
12% in the BM group (P \ .002). Similarly, chronic graft-versus-host disease (cGVHD; at 2 years) was
somewhat higher in the PBSC group with 43% 6 3% versus 35% 6 6% in the BM group, respectively
(P 5 .04). The 2-year probabilities of leukemia-free survival (LFS) were 46% 6 3% for the PBSC group
in comparison to 43% 6 6% for the BM transplant group (P 5 NS), whereas relapse incidence was signif-
icantly higher in the BM versus the PB transplant group: 46% 6 6% versus 32% 6 3%, respectively (P 5
.014). Non-relapse mortality (NRM) was significantly higher for the PBSC versus the BM group: 28% 6 2%sion of Hematology and Bone Marrow Transplanta-
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Biol Blood Marrow Transplant 18:1422-1429, 2012 1423PB versus BM in RIC-alloSCTversus 13% 6 4%, respectively (P 5 .004). In multivariate analysis, after adjustment for differences between
both groups, the PBSC group was associated with a higher incidence of aGVHD (grade II-IV; hazard ratio
[HR] 5 2.33; P 5 .06), higher NRM (HR 5 2.3; P 5 .015), and a decreased relapse incidence (HR, 0.61; P 5
.02) with no statistical difference of LFS between the 2 groups (P 5 .88). In conclusion, our results indicate
significantly higher incidence of aGVHD and NRM and a lower incidence of relapse but not statistically
different LFS comparing unrelated PBSC to BM grafts after RIC-alloSCT.
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Stem cell mobilization, RemissionINTRODUCTION
Allogeneic hematopoietic stem cell transplant
(alloSCT) is a potentially curative treatment for ad-
vanced or high-risk acute myeloid leukemia (AML)
[1]. However, myeloablative conditioning may be
associated with unacceptably increased toxicity in el-
derly, medically unfit, or heavily pretreated patients.
The introduction of alloSCT with reduced-intensity
conditioning (RIC) allowed extension of alloSCT to
a much wider patient population by reducing the
toxicity and exploiting the graft-versus-lymphoma
(GVL) effect as the primary curative approach [2-5].
As engraftment post-alloSCT has been shown to cor-
relate with dose intensity, the engraftment post-RIC is
mainly based on strong, but transient immunosuppres-
sion and high cell dose [6-9]. Indeed, most of the RIC
alloSCTs are performed with mobilized peripheral
blood stem cell (PBSC) grafts rather than bone
marrow (BM) grafts [10], as PBSCs have been demon-
strated to contain significantly higher numbers of
CD341 hematopoietic stem cells compared with
BM grafts [11-15]. However, the stem cell source
and type of graft may have different implications
on transplantation outcome in the RIC setting
compared to the myeloablative setting. In the
myeloablative setting with BM grafts, the infusion of
high doses of progenitor cells has a favorable
impact on transplantation outcome, due to faster
hematopoietic and immune recovery [16]. In contrast,
when using granulocyte colony-stimulating factor
(G-CSF)-mobilized PBSCs in the context of myeloa-
blative alloSCT, the infusion of a high number of
CD341 cells increased the incidence of extensive
chronic graft-versus-host disease (cGVHD), which ad-
versely affected outcome due to higher transplant-
related mortality (TRM) [17-19].
In contrast to the availability of extensive literature
comparing mobilized PBSC grafts to BM grafts in
sibling myeloablative alloSCT [13,17-22], data in the
unrelated setting is still sparse [23]. In the study by
Eapen et al. [24], the authors compared the outcome
after 331 PBSC and 586 transplants in adults with leu-
kemia and myelodysplastic syndrome. Rates of acute
graft-versus-host disease (aGVHD) and cGVHDwere significantly higher with PBSC than with BM
transplants [13,17-22], whereas TRM, relapse,
leukemia-free survival (LFS), and overall survival
were similar [23]. Similar results were also observed
recently in another analysis from the Center for Inter-
national Blood and Marrow Transplant Research that
compared the effect of graft source in unrelated donor
(URD) hematopoietic stem cell transplant in adults
with acute leukemia [24]. In both analyses, patients
were conditioned with myeloablative preparative regi-
mens [23,24]. With this background, and given the
increased usage of both URDs and RIC alloSCT in
patients with acute leukemia [25,26], this report
aimed to compare outcomes of PBSC versus BM in
the setting of RIC alloSCT in patients with AML in
remission undergoing alloSCT from matched
unrelated donors (MUDs).PATIENTS AND METHODS
Study Design and Data Collection
This was a retrospective multicenter analysis. Data
of adult patients with AML receiving RIC alloSCT us-
ing PBSC or BM from an MUD were provided by the
Acute Leukemia Working Party of the European
Group for Blood and Marrow Transplantation
(EBMT) group. The EBMT registry is a voluntary
working group of more than 500 transplantation cen-
ters, participants of which are required once a year to
report all consecutive stem cell transplants and
follow-up. The Acute Leukemia Working Party of
the EBMT group approved this study.
Selection Criteria
The study included patients with AML receiving
first RIC alloSCT in complete remission (CR) from
an MUD using PBSCs or BM, who: (1) were age
$16 years at time of transplantation; (2) were trans-
planted between the years 2000 and 2007; (3) had re-
ceived an RIC regimen defined as the use of
fludarabine associated with low-dose total body irradi-
ation (TBI;#6 Gy) or busulfan (total dose#8 mg/kg)
or other immunosuppressive or cytotoxic drugs such as
melphalan or cyclophosphamide as defined by the
1424 Biol Blood Marrow Transplant 18:1422-1429, 2012A. Nagler et al.EBMT criteria [27,28]; and (4) were patients whose
clinical data on outcomes were adequate. A total of
602 alloSCT recipients from 123 transplantation
centers met these eligibility criteria. Exclusion
criteria were: previous allogeneic transplant, cord
blood transplant, and myeloablative conditioning
alloSCT. URDs were selected on the basis of
serological typing at class I (HLA-A and HLA-B)
and molecular typing of class II (DRB1) alleles. An
MUD was defined as the absence of an antigenic mis-
match at class I or a molecular mismatch at class II.
Statistical Analysis and Study Endpoints
The primary endpoint was LFS. Secondary end-
points were non-relapse mortality (NRM), engraft-
ment, aGVHD, cGVHD, and relapse incidence (RI).
Patient, disease, and transplant-related variables of
both groups were compared, using the chi-square sta-
tistic for categorical and the Mann-Whitney test for
continuous variables. Characteristics considered were
recipient age at transplantation, recipient and donor
sex, recipient and donor cytomegalovirus (CMV) sta-
tus, disease features (WBC at diagnosis, AML French,
American, British [FAB] subtype, cytogenetics, disease
stage at transplantation), and alloSCT characteristics
(year of transplantation, interval between diagnosis
and transplantation, conditioning regimen). LFS was
defined as survival without evidence of relapse or pro-
gression. Relapse was defined as any event related to
the reoccurrence of the disease. NRM was defined as
death from any cause without previous relapse or pro-
gression. The aGVHD and cGVHD were graded and
staged by standard criteria. Cumulative incidence
curves were used for RI and NRM in a competing
risk setting [29]. For estimation of cGVHD, death
was considered as a competing event. Probabilities of
LFS were calculated using the Kaplan-Meier method,
and the log-rank test was used for univariate compari-
sons. For all prognostic analyses, the median value of
continuous variables was used as a cutoff point. All fac-
tors differing between the 2 groups with a P value less
than .15 were included in the final model. Associations
of patient and graft characteristics with outcomes were
evaluated in multivariate analyses using Cox propor-
tional hazards. All tests are 2-sided. The type I error
rate was fixed at 0.05 for determination of factors asso-
ciated with time-to-event outcomes. Statistical analy-
ses were performed with the SPSS (IBM Inc.,
Chicago, IL) and Splus (MathSoft, Inc., Seattle, WA)
software packages.RESULTS
Patient Characteristics
Six hundred two patients with AML were in-
cluded in this analysis. Five hundred eight patientsunderwent transplantation with G-CSF-mobilized
PBSCs grafts and 94 with BM grafts. This BM/
PBSC ratio reflects the current practice in favor
of PBSCs in this population of patients. The me-
dian age of the PBSC group was 57 years (range,
17-77 years) and of the BM group 51 years (range,
17-76 years), respectively (P \ .0001; Table 1).
Fifty-five percent of the PBSC group were men
and 45% were women, whereas in the BM group,
it was 69% and 31%, respectively (P 5 .72). Pa-
tients in the PBSC group underwent transplantation
in 2006 (range, 2000-2007), whereas patients in the
BM group underwent transplantation in 2005
(2000-2008), respectively (P \ .001; Table 1). Me-
dian follow-up of the whole study group was 17
months (range, 0.5-105 months). All patients were
in CR at alloSCT, per study inclusion criteria. In
the PBSC group, 61% of the patients were in first
complete remission (CR1) and 39% in second com-
plete remission (CR2), respectively, whereas in the
BM group, 60% of the patients were in CR1 and
40% at CR2, respectively (P 5 .79). Disease charac-
teristics also did not differ between the 2 study
groups. As outlined in Table 1, WBC at diagnosis
and FAB classification were not statistically signifi-
cantly different between the PBSC and BM groups.
Similarly, cytogenetic scores (ie, good, intermediate,
and poor risk groups) did not differ between the 2
groups (P 5 .79; Table 2). Median time from diag-
nosis to alloSCT was longer in BM alloSCT in
comparison to the PBSC transplants: 324 and 325
days versus 253 days, respectively (P \ .015 in
Table 2). Both groups were comparable for CMV
status of patients and donors, donor characteristics,
and gender (Table 2). The RIC protocols included
fludarabine and melphalan in 39% of the transplan-
tations, or fludarabine and busulfan in 54% of the
transplantations in both groups (Table 2; P 5
NS). However, more patients received low-dose
TBI in the PBSC group (36%) as compared to
only 5% in the BM group (P 5 .0001; Table 2).
The details of the GVHD prophylaxis regimen
were available for 377 patients (62 BM and 315
PBSC). Association of cyclosporine A and mycophe-
nolate mofetil was used in 146 patients who re-
ceived PBSCs, but in only 8 patients who received
BM (P\ .0001). Thus, it was not possible to adjust
the comparison on this variable.Engraftment
Ninety-seven percent and 96% of patients in the
BM and peripheral blood (PB) groups engrafted, re-
spectively. Twenty patients (4%) in the PBSC group
and 2 patients (3%) in the BM group did not engraft
(P 5 NS). Only 1 patient from each group had a late
loss of the graft (Table 3).
Table 1. Patient and Disease Characteristics
Patient Characteristics PBSC BM P Value
Number of patients 508 94
Median age in years (range) 57 (17-77) 51 (17-76) <.0001
Gender M: 281 (55.4%) M: 63 (69.2%) .72
F: 226 (44.6%) F: 28 (30.8%)
CMV status Neg 5 111 (33.9%) Neg 5 19 (29.7%) .51
Pos 5 216 (66.1%) Pos 5 45 (70.3%)
Transplantation year 2006 (2000-2007) 2005 (2000-2007) .001
Disease status* CR1 5 310 (61%) CR1 5 56 (60%) .79
CR2 5 198 (39%) CR2 5 38 (40%)
WBC† (109/L) median (range) 10.0 (0.5-461) 10.9 (0.7-145) .79
FAB classification M1 M2-M3 5 51.5% M1 M2-M3 5 47.1% .33
M4-M5 5 34.2% M4-M5 5 42.9%
M0 M6 M7 5 14.3% M0 M6 M7 5 10%
PBSC indicates peripheral blood stem cells; BM, bone marrow; CMV, cytomegalovirus; CR1, first complete remission; CR2, second complete remission;
Neg, negative; Pos, positive; FAB, French, American, British.
*At transplantation.
†At diagnosis.
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NRM at 2 years was significantly higher in pa-
tients with AML who underwent transplantation
with PBSC grafts (cumulative incidence, 28% 6 2%)
in comparison with those transplanted with BM
grafts (13% 6 4%; P Gray test 5 .004; P Cox 5
.015; Figure 1). Other parameters including age
(above or below 55 years), disease status (CR2 versus
CR1), conditioning regimen (yes or no low dose
TBI), year of alloSCT, and interval from diagnosis
to alloSCT (longer or shorter than 262 days) were
not found as independent predictive factors for
NRM in multivariable analysis (Table 4).Table 2. Disease and Transplant Characteristics
Patients’ Characteristics PBSC BM P Value
Number of patients 508 94
Cytogenetic classification .79
Good risk 16 (7.7%) 4 (8.5%)
Intermediate risk 148 (70.8%) 35 (74.5%)
Poor risk 45 (21.5%) 8 (17%)
Donor characteristics
Gender M: 358 (72%) M: 63 (69.2%) .59
F: 139 (28%) F: 28 (30.8%)
Female donor to male
recipient
53 (10.7%) 10 (11%) .93
CMV status Neg 5 186 (56.9%) Neg 5 33 (52.4%) .51
Pos 5 141 (43.1%) Pos 5 30 (47.6%)
Conditioning
No TBI 324 (64.4%) 87 (94.6%) .0001
With TBI 179 (35.6%) 5 (5.4%)
If chemotherapy alone:
Flu + Melfalan 37% 39%
Flu + Busulfan 51% 55%
Cy + other 12% 6% .22
Median time from
diagnosis to
transplantation (days)
253 325 <.015
PBSC indicates peripheral blood stem cells; BM, bone marrow; CMV,
cytomegalovirus; Neg, negative; Pos, positive; TBI, total body irradiation;
Flu, fludarabine; Cy, cyclophosphamide.Relapse Rate
Relapse rate was significantly higher (46% 6
6%) in patients who underwent transplantation
with BM grafts as compared with those who under-
went transplantation with PBSC grafts (32% 6 3%),
respectively (P Gray test 5 .014; P Cox 5 .019;
Figure 2). Other parameters including age (above
or below 55 years; P 5 .053), disease status (CR2
versus CR1), conditioning regimen (yes or no low
dose TBI), year of alloSCT, and interval from diag-
nosis to alloSCT (longer or shorter than 262 days)
were not found as independent predictive factors
for relapse rate in multivariable analysis (Table 4).
GVHD
Incidence of aGVHD was significantly higher in
patients with AML who underwent transplantation
from mobilized PBSC grafts in comparison with
those who underwent transplantation with BM
grafts (Table 3). Because BM recipients were youn-
ger, the comparison between the PBSC and BM
groups was adjusted for recipient age. The fre-
quency of grades II to IV aGVHD was significantly
lower in patients who underwent transplantationTable 3. Transplantation Outcome
Patients’ Characteristics PBSC BM P Value
Number of patients 508 94
Engraftment 473 (96%) 89 (97%) NS
No engraftment 20 (4%) 2 (3%)
Lost graft 1 (0.1%) 1 (0.02%)
aGVHD
Grades II-IV 131 (27.1%) 11 (12.1%) .002
Grades III-IV 44 (9.1%) 2 (2.2%) .03
cGVHD, 2 years 43% ± 3% 35% ± 6% .04
Median follow-up in months (range) 16 (1-94) 24 (1-104) .07
PBSC indicates peripheral blood stem cells; BM, bone marrow; NS, not
significant; aGVHD, acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease.
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Figure 1. Probability of 2-year non-relapse mortality (NRM) after
reduced-intensity conditioning (RIC) allogeneic stem cell transplant
(alloSCT) with mobilized peripheral blood stem cell graft (PBSC;
n 5 508) versus bone marrow (BM) graft (n 5 94; P Gray test 5
.004; P Cox 5 .015).
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Figure 3. Probability of chronic graft-versus-host disease (cGVHD) at
2 years after reduced-intensity conditioning (RIC) allogeneic stem cell
transplant (alloSCT) with mobilized peripheral blood stem cell (PBSC)
graft (n 5 508) versus bone marrow (BM) graft (n5 94; P Gray 5 .04).
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those who underwent transplantation from mobi-
lized PBSC grafts (P 5 .002; Table 3). Furthermore,
severe aGVHD grades III to IV was significantly
higher in PBSC alloSCT versus BM alloSCT:
9.1% versus 2.2%, respectively (Table 3; P 5 .03).
No patient in the BM group had grade IV aGVHD
in comparison with 17 patients (3%) in the PBSC
group, respectively. Similarly, the incidence of
cGVHD was significantly higher in the PBSC group
(43% 6 3%) as compared with the BM group
(35% 6 6%; P 5 .04; Figure 3).Transplantation Outcome
LFS rates at 2 years were similar between both
groups: 46% 6 3% in patients who underwent trans-
plantation from mobilized PBSC grafts versus
43%6 6% in patients who underwent transplantation1 2 3 4 5
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Figure 2. Probability of relapse after reduced-intensity conditioning
(RIC) allogeneic stem cell transplant (alloSCT) with mobilized periph-
eral blood stem cell graft (PBSC; n 5 508) versus bone marrow (BM)
graft (n 5 94; P Gray 5 .014; P Cox 5 .019).from BM grafts (Figure 4; P log-rank 5 .70; P Cox 5
.88). In multivariable analysis, the type of graft (PBSC
versus BM), disease status (CR2 versus CR1), condi-
tioning regimen (with or without low-dose TBI),
year of transplantation (after or before 2005), and
time from diagnosis to alloSCT (longer or shorter
than 262 days) were not found as predictive factors
for LFS. However, age (above or below 55 years)
reached statistical significance (P 5 .02) (Table 4).DISCUSSION
In the current study, we have compared G-CSF-
mobilized PBSC and BM as a graft source for unre-
lated alloSCT post-RIC preparative regimens for
patients with AML in remission. Our data indicates
that PBSC grafts are associated with higher incidence
of both aGVHD and cGVHD and NRM, but with
a lower incidence of relapse, with LFS being compara-
ble between the PBSC and BM groups. Unfortunately,Figure 4. Probability of leukemia-free-survival (LFS) at 2 years after
reduced-intensity conditioning (RIC) allogeneic stem cell transplant
(alloSCT) with mobilized peripheral blood stem cell (PBSC) graft
(n 5 508) versus bone marrow (BM) graft (n 5 94; P log-rank 5 .70;
P Cox 5 .88).
Table 4. Multivariable Analysis
NRM P Value HR
95% CI
Inf Sup
PBSC versus BM .015 2.30 1.17 4.50
Age >55 years .18 1.29 0.89 1.86
CR2 versus CR1 .046 1.22 0.72 2.06
TBI versus no .81 0.95 0.65 1.40
Year $2006 .59 0.91 0.63 1.31
Diag to tx >262 days .32 1.30 0.77 2.21
RI
PBSC versus BM .019 0.61 0.41 0.92
Age >55 years .05 1.38 1.00 1.91
CR2 versus CR1 .24 1.32 0.83 2.11
TBI versus no .56 1.11 0.78 1.58
Year $2006 .75 1.05 0.76 1.45
Diag to tx >262 days .62 0.89 0.56 1.41
cGVHD
PBSC versus BM .18 1.40 0.85 2.30
Age >55 years .85 1.03 0.74 1.44
CR2 versus CR1 .74 0.92 0.58 1.47
TBI versus no .14 1.30 0.91 1.86
Year $2006 .66 1.08 0.77 1.50
Diag to tx >262 days .84 0.96 0.66 1.49
LFS
PBSC versus BM .88 1.03 0.73 1.44
Age >55 years .02 0.75 0.58 0.95
CR2 versus CR1 .16 0.78 0.55 1.11
TBI versus no .81 0.97 0.75 1.26
Year $2006 .91 1.01 0.80 1.29
Diag to tx >262 days .80 0.95 0.67 1.35
NRM indicates non-relapse mortality; PBSC, peripheral blood stem
cells; BM, bone marrow; CR2, second complete remission; CR1, first
complete remission; TBI, total body irradiation; RI, relapse incidence;
Diag to tx, time from diagnosis to transplantation; cGVHD, chronic
graft-versus-host disease; LFS, leukemia-free survival; HR, hazard ratio;
CI, confidence interval; Inf, inferior limit of 95% Confidence Interval;
Sup, superior limit of 95% CI.
Biol Blood Marrow Transplant 18:1422-1429, 2012 1427PB versus BM in RIC-alloSCTthis study was not able to assess the impact of stem cell
source according to disease status at transplantation,
given the relatively small number of BM recipients.
Also, other weaknesses of this study were the lack of
full cytogenetic data and the diversity of the so-called
RIC regimens.
Previous studies comparing PBSC to BM in allo-
SCT differ from the current study in several aspects:
(1) the donors were mostly HLA matched siblings;
(2) the conditioning was a standard myeloablative
one; (3) patients with various hematological malignan-
cies were usually included; and (4) disease status was
heterogeneous, including patients in remission as well
as patients with active disease [13,17-22,30]. Except
for 2 studies [21,31], in most of these comparisons
on sibling donor alloSCT after myeloablative condi-
tioning, incidence of either aGVHD [21] or cGVHD
[18,22,32,33] or both [17,19,29,34] was higher
posttransplantation from PBSC grafts as compared
with BM grafts. In this respect, our study in the RIC
setting and with URDs suggested a higher incidence
of GVHD ($grade II 27%; severe grade III-IV 8.7%;
and chronic 43 6 3%) post-PBSC transplantation as
comparedwith 12%, 2%, and 35%6 6%, respectively,
post-BM transplantation. Interestingly, GVHD inci-dence in our cohort was not different from the inci-
dence published in previous studies comparing PBSC
toBM in the sibling setting reporting, in general, an in-
cidence of 30% to 40% for grade II to IV aGVHD,
14% to 20% for grade III to IV aGVHD, and 30% to
50% for cGVHD in PBSC transplants versus 25% to
30%, 5% to 15%, and 15% to 30%, respectively, for
BM transplants [17,19,30,32,34,35]. Such similarities
with the sibling myeloablative setting is of high
interest and may indicate the improvement in
unrelated transplantations on one hand [30,36], but
also the fact that incidence of GVHD may be reduced
in RIC versus myeloablative alloSCT [37,38] and that
GVHD incidence is lower in patients with remission
as compared with patients in relapse [37].
As for NRM, we observed a significantly lower in-
cidence of NRM with BM (13% 6 4%) as compared
to 28% 6 2% with PBSC. The lower incidence of
NRM with BM grafts is likely related to the lower in-
cidence of aGVHD and cGVHD. Indeed, similar re-
sults were observed in other comparisons in the
sibling myeloablative setting. Champlin et al. [20]
reported an incidence of 18% versus 28% with BM
versus PBSC grafts, respectively, for 1 year NRM.
Similar results were also reported by Couban et al.
[34] and Nagafugi et al. [29], who observed a trend
for lower NRM with BM grafts. In contrast, Ringden
et al. [18], Schmitz et al. [22], and the Stem Cell Tria-
lists’ Collaborative Group [19], as well as the Spanish
cooperative group [33], found no difference in NRM
between transplantations with PBSC versus BM grafts.
The difference between the various comparisons in
the myeloablative sibling setting may be due to differ-
ences in disease categories, disease status (remission
versus active disease), and conditioning regimens
(with or without TBI). The relatively low 2-year
TRM in our comparison, especially with BM grafts,
confirms the potential benefit of RIC conditioning
regimens that have resulted in a significant reduction
of NRM in most, if not all, studies reporting alloSCT
with RIC [2-6,36,39].
Interestingly, in multivariable analysis, no other
transplant variable was found to be predictive of
NRM. As for relapse, we observed a lower relapse rate
with PBSC grafts as compared with BM grafts, which
is suggestive of a stronger graft-versus-leukemia
(GVL) effect with PBSC grafts that are known to con-
tain about 20- to 25-foldmore cytotoxicT cells andnat-
ural killer cells compared with BM grafts [11,12]. This,
most probably, is also the reason for the higher
incidence of GVHD, and especially cGVHD,
observed with PBSC grafts, especially those with
a higher number of CD341 cells [17,19,30,34,37]. As
for the relapse rate post-PBSCversusBM inmyeloabla-
tive transplants fromHLAmatched donors, conflicting
results were reported previously. Couban et al. [34] and
others [22,40-43] reported a lower relapse rate with
1428 Biol Blood Marrow Transplant 18:1422-1429, 2012A. Nagler et al.PBSC, whereas others did not find differences between
the 2 groups [18,20,21,30,34]. Such discrepancies
might again be related to the type of malignancy and
disease status at transplantation [19,21,31,44].
Also, the observed correlation between decreased
relapse and higher incidence of cGVHD in the
RIC setting supports a close correlation between
cGVHD and the GVL effect after RIC alloSCT, as
described previously [37,45,46]. Most important, in
multivariable analysis, the graft source (ie, PBSC
versus BM) was the only significant factor predictive
for relapse.
Comparison between PBSC and BM in the URD
transplant setting was previously reported in 2 studies
performed by the Center for International Blood and
Marrow Transplant Research [23,24] in adults with
acute (AML and ALL) and chronic leukemia, as well
as myelodysplastic syndrome, in remission or relapse
who received myeloablative conditioning, and in
another pediatric small study including mainly acute
leukemias after myeloablative conditioning [47]. In
the latter studies [23,24,47], the main differences
found between BM and PBSC groups (aside from
kinetics of engraftment), was the incidence of
aGVHD and cGVHD.
As for the RIC setting, there is only 1 previously
published comparison of PBSC versus BM grafts con-
ducted in patients withmyelomawho received alloSCT
from sibling donors [48]. The authors observed a re-
duced incidence of cGVHD in BM versus PBSC trans-
plants but NRM, relapse rate, and progression-free
survival were not different between the groups.
In conclusion, despite its retrospective nature, the
current study comparing PBSC and BM grafts in a ho-
mogeneous group of patients with AML in remission
receiving an RIC alloSCT from an MUD suggests
similar final survival in the results; only LFS has shown
outcomes between PBSC and BM. Whether PBSC
should be the preferred stem cell source in patients
with advanced disease needs to be further investigated.
Randomized studies comparing G-CSF-mobilized
PBSC versus BM grafts for patients with AML in re-
mission undergoing RIC alloSCT are indicated.
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